By Frank Prenesti
Date: Tuesday 29 Dec 2020
LONDON (ShareCast) - (Sharecast News) - AstraZeneca and Merck's Lynparza has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers, the UK-based pharmaceutical company said on Tuesday.
The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare are based on positive results from the PAOLA-1, PROfound and POLO Phase III trials, which each were published in The New England Journal of Medicine.
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 129.48 |
Change Today | $ 0.11 |
% Change | 0.09 % |
52 Week High | $131.95 |
52 Week Low | $100.18 |
Volume | 7,338,462 |
Shares Issued | 2,531.63m |
Market Cap | $327,796m |
RiskGrade | 92 |
Strong Buy | 11 |
Buy | 12 |
Neutral | 3 |
Sell | 0 |
Strong Sell | 0 |
Total | 26 |
Time | Volume / Share Price |
16:00 | 1,212,507 @ $129.48 |
15:59 | 200 @ $129.48 |
15:59 | 500 @ $129.48 |
15:59 | 200 @ $129.48 |
15:59 | 100 @ $129.50 |
You are here: research